July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Establishing a Colony of Non-human Primates with Cystoid Macular Edema
Author Affiliations & Notes
  • Laura Belen
    Pre-clinical, Ora Inc, Andover, Massachusetts, United States
  • Kortni Violette
    Pre-clinical, Ora Inc, Andover, Massachusetts, United States
  • Christopher Schillo
    Pre-clinical, Ora Inc, Andover, Massachusetts, United States
  • Christopher Gallotta
    Pre-clinical, Ora Inc, Andover, Massachusetts, United States
  • Christian Grant
    Biomere, Inc, Worcester, Massachusetts, United States
  • Leslie Jost
    Biomere, Inc, Worcester, Massachusetts, United States
  • David Hollander
    Ora, Inc, Andover, Massachusetts, United States
  • Andy Whitlock
    Pre-clinical, Ora Inc, Andover, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Laura Belen, Ora, Inc (E); Kortni Violette, Ora, Inc (E); Christopher Schillo, Ora, Inc (E); Christopher Gallotta, Ora, Inc (E); Christian Grant, Biomere, Inc (E); Leslie Jost, Biomere, Inc (E); David Hollander, Ora, Inc (E); Andy Whitlock, Ora, Inc (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 391. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Laura Belen, Kortni Violette, Christopher Schillo, Christopher Gallotta, Christian Grant, Leslie Jost, David Hollander, Andy Whitlock; Establishing a Colony of Non-human Primates with Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2018;59(9):391.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To date, there are no reliable models that accurately reproduce the disease traits of chronic vascular leakage or edema associated with retinal disorders such as Cystoid Macular Edema (CME), wet AMD, or diabetic macular edema. Such a model would be invaluable in assessing efficacy and duration of action of new treatments for retinal vascular disease. This abstract describes development of a novel model of chronic CME in a non-human primate (NHP), cynomologus macaque, by utilizing intravitreal injection of the glutamine synthase inhibitor DL-2-Aminoadipic acid (DLAAA).

Methods : Non-naïve cynomologus NHPs received intravitreal (IVT) injection of DLAAA (2.5-5mg) in one eye. Animals underwent baseline and weekly optical coherence tomography (OCT) and fluorescein angiography (FA) until sufficient disease phenotype became established. This included (but was not limited to) intra-retinal cysts, macular edema, and vascular leakage. Once the disease state plateaued, vascular endothelial growth factor (VEGF) inhibitor was administered to assess whether the induced disease state was responsive to this treatment modality. Eyes were monitored via OCT and FA post treatment to follow disease.

Results : IVT injection of DLAAA produced a prolonged and substantial retinal disease that presented most prominently via OCT with signs of macular edema and intra-retinal cysts, but with little to no uveitis thus preserving the neural retina. The edema was evident within 4 weeks and plateaued by10 weeks. Once the pathological phenotype was stable, treatment with anti-VEGF agents yielded a partial to full resolution of the disease characteristics that lasted for 4-6 weeks, followed by a recurrence of the disease state.

Conclusions : The results demonstrate that this model paradigm can be used to establish sustained macular edema pathology in a non-human primate that is not associated with uveitis, preserved the neural retina, and is responsive to current standards of care. This model will allow us to create a stable colony of animals with CME that can be used as an essential tool for testing the efficacy of novel therapeutics designed to treat retina diseases associated with vascular leakage including CME, wet-AMD, and diabetic macular edema.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×